Pharma Gets Green Light for Trade Zone Drug Making in PA
Published Date: 3/26/2025
Notice
Summary
PCI Pharma Services got the green light to make pharmaceutical products at their Croydon and Philadelphia sites inside Foreign-Trade Zone 35. This means they can produce medicines with special trade benefits, helping them save money and speed up operations. The approval was finalized on March 21, 2025, so things are officially rolling now!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
PCI Authorized to Produce in FTZ 35
PCI Pharma Services was authorized to carry out production activity for pharmaceutical products inside Foreign-Trade Zone 35 (Subzone 35L) at its Croydon and Philadelphia, Pennsylvania facilities. The applicant submitted the notification on November 21, 2024 and the FTZ Board notified the applicant of authorization on March 21, 2025.
Production Subject to FTZ Act and Rules
The authorized production activity for PCI Pharma Services is subject to the Foreign-Trade Zones Act and the FTZ Board's regulations, including section 400.14 of 15 CFR part 400. The FTZ Board processed the notification under the FTZ Board regulations and issued the authorization on March 21, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in